Table 5.
Pathways to triple therapy split by lung function grade
| Treatment pathway from date of COPD diagnosis | Lung function grade (GOLD group)
|
|||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| n (%) | n (%) | n (%) | n (%) | |
| ICS + LABA → ICS + LABA + LAMA | 75 (25) | 401 (24) | 327 (26) | 66 (23) |
| ICS + LABA + LAMA | 35 (12) | 160 (10) | 119 (9) | 27 (9) |
| ICS → ICS + LABA → ICS + LABA + LAMA | 22 (8) | 131 (8) | 128 (10) | 29 (10) |
| None → ICS + LABA → ICS + LABA + LAMA | 21 (7) | 124 (8) | 96 (8) | 27 (9) |
| SABA → ICS + LABA → ICS + LABA + LAMA | 12 (4.1) | 86 (5) | 51 (4.0) | 12 (4.2) |
| None → ICS + LABA + LAMA | 13 (4.4) | 57 (3.4) | 64 (5) | 16 (6) |
| None → LAMA → ICS + LABA + LAMA | 9 (3.1) | 84 (5) | 41 (3.2) | 13 (4.5) |
| None → ICS → ICS + LABA → ICS + LABA + LAMA | 12 (4.1) | 54 (3.3) | 45 (3.6) | 7 (2.4) |
| LAMA → ICS + LABA + LAMA | 5 (1.7) | 63 (3.8) | 30 (2.4) | 9 (3.1) |
| SABA → ICS → ICS + LABA → ICS + LABA + LAMA | 8 (2.7) | 40 (2.4) | 39 (3.1) | 4 (1.4) |
| SABA + SAMA → ICS + LABA → ICS + LABA + LAMA | 7 (2.4) | 35 (2.1) | 41 (3.2) | 7 (2.4) |
| SABA → LAMA → ICS + LABA + LAMA | 8 (2.7) | 48 (2.9) | 20 (1.6) | 1 (0.3) |
| ICS → ICS + LAMA → ICS + LABA + LAMA | 7 (2.4) | 33 (2.0) | 20 (1.6) | 6 (2.1) |
| ICS → ICS + LABA + LAMA | 5 (1.7) | 26 (1.6) | 16 (1.3) | 3 (1.0) |
| ICS + LAMA → ICS + LABA + LAMA | 6 (2.0) | 19 (1.1) | 16 (1.3) | 6 (2.1) |
| LABA → ICS + LABA → ICS + LABA + LAMA | 3 (1.0) | 21 (1.3) | 10 (0.8) | 6 (2.1) |
| None → LABA → ICS + LABA → ICS + LABA + LAMA | 5 (1.7) | 15 (0.9) | 14 (1.1) | 4 (1.4) |
| Other non-frequent pathways | 42 (14) | 263 (16) | 187 (15) | 43 (15) |
| Total | 295 (100) | 1,660 (100) | 1,264 (100) | 286 (100) |
Notes: Pathways with a percent frequency of less than 1% were grouped under the category “other non-frequent pathways”. The first drug listing in the treatment pathway was considered to be the patient’s initial therapy, and the second drug listing was the prescription after the initial date of COPD diagnosis. All percentage values >5.0 were rounded up.
Abbreviations: GOLD, The Global initiative for chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.